Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome

International Heart Journal

Volumn 48, Issue 3, 2007, Pages 417-422

  Miwa, Kenji ^a   Matsubara, Takashi ^a   Uno, Yoshihide ^a   Yasuda, Toshihiko ^a   Sakata, Kenji ^a   Tsuda, Toyonobu ^a   Kanaya, Honin ^a  

^a ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Beraprost; CREST syndrome; Pulmonary artery hypertension; Sildenafil

Indexed keywords

BERAPROST; SILDENAFIL;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DYSPNEA; EXERCISE TEST; FEMALE; FLUSHING; HEART HEMODYNAMICS; HEART PALPITATION; HUMAN; JAPANESE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MONOTHERAPY; OXYGEN SATURATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; SINGLE DRUG DOSE; SYNDROME CREST;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, ORAL; CREST SYNDROME; CRYOPROTECTIVE AGENTS; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY WEDGE PRESSURE; PURINES; SULFONES; VASODILATOR AGENTS;

EID: 34547531940     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.48.417     Document Type: Article

References (14)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-23.
2. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-206.
3. Zhao J, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Ciculation 2001; 104: 424-8.
4. Kleinsasser A, Loeckinger A, Hoermann C. Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med 2001; 163: 339-43.
5. Ghofrani HA, Schermuly RT, Row F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: 1139-41.
6. Nishio S, Kurumatani H. Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue. Nippon Yakurigaku Zasshi 2001; 117: 123-30. (Review) (Japanese)
7. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-502.
8. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-25.
9. Watanabe H, Ohashi K, Takeuchi K, et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 2002; 71: 398-402.
10. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-403.
11. Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprosterol in patients with pulmonary arterial hypertension. Chest 2003; 123: 1293-5.
12. Niwano Y, Arai M, Tomaru, K, Uchiyama T, Ohyama Y, Kurabayashi M. Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI2 signal and NO pathways. Circ Res 2003; 93: 523-30.
13. Itoh T, Nagaya N, Fujii T, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 34-8.
14. Ikeda D, Tsujino I, Ohira H, et al. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. J Cardiovasc Pharmacol 2005; 45: 286-9.